𝔖 Bobbio Scriptorium

✦ LIBER ✦

Cisplatin or carboplatin plus paclitaxel for advanced ovarian cancer had similar rates of progression free survival

Book ID: 116416109
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 69 KB
Volume: 6
Category: Article
ISSN: 1361-259X
DOI: 10.1016/j.ebobgyn.2004.04.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

37 Paclitaxel plus carboplatin versus pa

37 Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): long-term efficacy results

✍ G. Aravantinos; G. Fountzlias; P. Kosmidis; Ma. Dimopoulos; Gp. Stathopoulos; N. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Moderately high-dose carboplatin with pa

Moderately high-dose carboplatin with paclitaxel and intraperitoneal cisplatin improves progression-free survival but has higher toxicity than standard intravenous cisplatin and paclitaxel for small volume ovarian cancer

✍ Mario De Lena 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Randomized phase 3 trial of interferon g

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

✍ David S. Alberts; Christian Marth; Ronald D. Alvarez; Gary Johnson; Mariusz Bidz 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 233 KB

Phase II study of intravenous bevacizuma

Phase II study of intravenous bevacizumab (bev) and paclitaxel (pac), and intraperitoneal (ip) cisplatin (c), followed by bevacizumab (bev) maintenance, for advanced ovarian cancer: A report on progression-free survival (PFS) and toxicity

✍ L. Perry; G. Lanneau; J. Curiel; C. Mathews; K. Moxley; L. Landrum; K. Moore; J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 67 KB

First-line treatment of ovarian/tubal/pe

First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

✍ G.B. KRISTENSEN; I. VERGOTE; G. STUART; J.M. Del CAMPO; J. KÆRN; M. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB

6570 POSTER Results for progression-free

6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology

✍ Sandler, A.; Reck, M.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB